Forward Pharma’s IP rights impress
The Danish biotech company Forward Pharma has brought Genmab CEO Jan van de Winkel into its board of directors. Here, he explains his reasons for accepting the post.
BY BENJAMIN WERNER CHRISTENSEN
Forward Pharma, the Danish biotech company headed by major investor Florian Schönharting, recently announced that it had convinced Jan van de Winkel to join its board of directors. MedWatch spoke to the Genmab boss about his reason for joining Forward Pharma.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Danish company to wage war on drug giant
For abonnenter
Biotech boss joins Forward Pharma’s board
For abonnenter
